|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||CA125 antigen purified from human ovarian carcinoma.|
|Contains||0.09% sodium azide|
|Storage Conditions||4°C or -20°C if preferred|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-74328 recognizes the epitope specificity group B, similar to the M-11 antibody.
A suggested positive control for immunohistochemical applications is lung adenocarcinoma, serosal ovarian adenocarcinoma or urinary bladder adenocarcinoma tissue.
Ovarian cancer mucin CA125 (also known as MUCIN 16) consists of a short cytoplasmic tail, a transmembrane domain and an exceptionally large glycosylated extracellular domain. The extracellular domain is dominated by a large number of 156-amino acid repeat units, over 60 in all. These repeats are known to bind the antibodies OC125 and M11. CA125 is present within normal ovarian, endometrium endocervix and fallopian tissue, but levels are elevated in over 90% of women with advanced ovarian cancer. CA125 levels may also be elevated in other cancers and non-cancerous conditions such as peritonitis, endometriosis and liver cirrhosis. Levels may also fluctuate during the menstrual cycyle and occasionally increases in pregnancy, making CA125 an unreliable marker for ovarian cancer in premenopausal women. The function of CA125 in healthy tissue is unknown but it is thought to provide a protective lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 was conducted by the International Society of Oncology and BioMarkers (ISOBM) to contain two major antigenic domains.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.